Douglas Cole is a physician-investor at Flagship Pioneering who practiced medicine before entering venture capital, giving him a clinician's perspective on which platforms can become real therapies rather than just interesting science. He has spent over two decades at Flagship conceiving and building life science companies from the ground up, repeatedly founding and chairing platform biotech companies like Sigilon Therapeutics, Repertoire Immune Medicines, and Foghorn Therapeutics that focus on complex discovery platforms such as chromatin regulation, immune repertoire mapping, and encapsulated cell therapies. Douglas Cole is a physician-investor at Flagship Pioneering who practiced medicine before entering venture capital, giving him a clinician's perspective on which platforms can become real therapies rather than just interesting science. He has spent over two decades at Flagship conceiving and building life science companies from the ground up, repeatedly founding and chairing platform biotech companies like Sigilon Therapeutics, Repertoire Immune Medicines, and Foghorn Therapeutics that focus on complex discovery platforms such as chromatin regulation, immune repertoire mapping, and encapsulated cell therapies.